Literature DB >> 11334137

Vascular smooth muscle cell phenotypes in primary pulmonary hypertension.

Y Mitani1, M Ueda, R Komatsu, K Maruyama, R Nagai, M Matsumura, M Sakurai.   

Abstract

Primary pulmonary hypertension (PPH) is associated with specific structural alterations, including cellular intimal thickening, intimal fibrosis, and plexiform lesions. To determine the phenotypes of smooth muscle cells (SMCs) in such lesions, the authors conducted an immunohistochemical analysis of lung tissues from two patients with PPH, using two antimuscle actin antibodies, HHF35 and CGA7, and two anti-SMC myosin heavy chain markers, anti-SM1 and anti-SM2 antibodies and related antibodies. Cells that stained positive (+) with HHF35, CGA7, anti-SM1, and anti-SM2 were considered to be SMCs of a mature state. Conversely, those that stained positive with HHF35 and anti-SM1, but weakly positive (+/-) or negative (-) with CGA7 and anti-SM2, were considered to be SMCs exhibiting an immature state. Cellular intimal thickening was composed of SMCs of an immature phenotype (HHF35+, CGA7+/-, SM1+, SM2+/-), accompanied by the expression of fibronectin and the presence of macrophages; intimal fibrosis contained mature SMCs (HHF35+, CGA7+, SM1+, SM2+); and plexiform lesion consisted of proliferative endothelial cells (von Willebrand factor-positive cells, proliferating cell nuclear antigen-positive cells) and underlying immature SMCs (HHF35+, CGA7-, SM1+, SM2-) associated with fibronectin expression and macrophage infiltration. These findings suggest that smooth muscle cells with specific phenotypes may contribute to the development of specific vascular lesions in primary pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334137     DOI: 10.1183/09031936.01.17203160

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  20 in total

1.  Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.

Authors:  Helen Christou; Ossama M Reslan; Virak Mam; Alain F Tanbe; Sally H Vitali; Marlin Touma; Elena Arons; S Alex Mitsialis; Stella Kourembanas; Raouf A Khalil
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

Review 2.  [Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

Authors:  G Riemekasten; H Schulze-Koops
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

3.  Pulmonary hypertension in a patient with adult-onset Stills disease.

Authors:  Eisha Mubashir; M Mubashir Ahmed; Samina Hayat; Maureen Heldmann; Seth Mark Berney
Journal:  Clin Rheumatol       Date:  2006-07-27       Impact factor: 2.980

Review 4.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; John C Marecki; Amy Richter; Iwona Fijalkowska; Sonia Flores
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

5.  Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment.

Authors:  Danny Jonigk; Heiko Golpon; Clemens L Bockmeyer; Lavinia Maegel; Marius M Hoeper; Jens Gottlieb; Nils Nickel; Kais Hussein; Ulrich Maus; Ulrich Lehmann; Sabina Janciauskiene; Tobias Welte; Axel Haverich; Johanna Rische; Hans Kreipe; Florian Laenger
Journal:  Am J Pathol       Date:  2011-05-11       Impact factor: 4.307

6.  Smooth muscle myosin expression, isoform composition, and functional activities in rat corpus cavernosum altered by the streptozotocin-induced type 1 diabetes.

Authors:  Xinhua Zhang; Nirmala D Kanika; Arnold Melman; Michael E DiSanto
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-09-13       Impact factor: 4.310

7.  Sex hormones and vascular protection in pulmonary arterial hypertension.

Authors:  Helen A Christou; Raouf A Khalil
Journal:  J Cardiovasc Pharmacol       Date:  2010-11       Impact factor: 3.105

8.  Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.

Authors:  Helen Christou; Hannes Hudalla; Zoe Michael; Evgenia J Filatava; Jun Li; Minglin Zhu; Jose S Possomato-Vieira; Carlos Dias-Junior; Stella Kourembanas; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2017-12-06       Impact factor: 4.030

9.  Evidence for cell fusion is absent in vascular lesions associated with pulmonary arterial hypertension.

Authors:  S M Majka; M Skokan; L Wheeler; J Harral; S Gladson; E Burnham; J E Loyd; K R Stenmark; M Varella-Garcia; J West
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-10-17       Impact factor: 5.464

10.  HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension.

Authors:  Tatiana V Kudryashova; Dmitry A Goncharov; Andressa Pena; Neil Kelly; Rebecca Vanderpool; Jeff Baust; Ahasanul Kobir; William Shufesky; Ana L Mora; Adrian E Morelli; Jing Zhao; Kaori Ihida-Stansbury; Baojun Chang; Horace DeLisser; Rubin M Tuder; Steven M Kawut; Herman H W Silljé; Steven Shapiro; Yutong Zhao; Elena A Goncharova
Journal:  Am J Respir Crit Care Med       Date:  2016-10-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.